Document Detail

Advancing personalized cancer medicine in lung cancer.
MedLine Citation:
PMID:  23020726     Owner:  NLM     Status:  In-Data-Review    
Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients.
Laura E Macconaill
Related Documents :
16198466 - At home in hospital? interaction and stigma in people affected by cancer.
24768356 - Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine i...
23570406 - Challenges for the application of dna methylation biomarkers in molecular diagnostic te...
24238736 - Smoking and microrna dysregulation: a cancerous combination.
1506266 - Second primary cancer following laryngeal cancer with special reference to smoking habits.
8222256 - The fda's perspective on the evaluation of tumor marker tests.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  136     ISSN:  1543-2165     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1210-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Strategies for overcoming acquired resistance to epidermal growth factor receptor-targeted therapies...
Next Document:  The separation of benign and malignant mesothelial proliferations.